Skip to content
Back to resident companies

Cellbricks Therapeutics

Investment areas

  • Biotech / Life Sciences
Founders & Leadership
Simon MacKenzie
Alexander Leutner
Headquarters
Berlin, Germany

Building scalable clinical solutions to restore patient tissues and organs using our 3D bioprinting platform to develop biofabricated human tissue therapeutics

The Tough Tech problem we are solving

Current cell therapies often fail to provide lasting benefits because injected cells do not successfully engraft or integrate sustainably in patients’ tissues. This limits the effectiveness of treatments for many chronic and currently incurable diseases, leaving patients with compromised organ functions and few options. Additionally, replicating complex, vascularized human tissues in a scalable and implantable form remains a major scientific and manufacturing challenge in regenerative medicine.

About Our Solution

Cellbricks Therapeutics addresses this challenge by developing biofabricated, implantable tissue therapeutics using a proprietary light-based 3D bioprinting platform. This technology combines therapeutic cells with tailor-made biomaterials to create immune-compatible, vascularized human tissues at organ scale with high speed and resolution. These implantable tissues enable stable engraftment and functional integration, offering sustainable therapeutic effects and paving the way for new treatments that can restore or support organ function, ultimately improving patient longevity and quality of life.